This is a non-core endpoint: only basic statistics are computed.
Myelofibrosis
DOID EFO MESH Endpoint Browser
MYELOFIBROSIS
primary myelofibrosis: Myelofibrosis with myeloid metaplasia is a myeloproliferative disease with annual incidence of approximately 1 case per 100,000 individuals and age at diagnosis around 60 (an increased prevalence is noted in Ashkenazi Jews). Clinical manifestations depend on the type of blood cell affected and may include anemia, pallor, splenomegaly, hypermetabolic state, petechiae, ecchymosis, bleeding, lymphadenopathy, hepatomegaly, portal hypertension.
Endpoint definition
↥
FinnGen phenotype data
429209 individuals
Apply sex-specific rule None
429209
Check conditions None
429209
Check pre-conditions, main-only, mode, registry filters
Hospital Discharge: ICD-10
C94.5
Hospital discharge: ICD-9
2387A
Hospital discharge: ICD-8
209
Cause of death: ICD-10
C94.5
Cause of death: ICD-9
2387A
Cause of death: ICD-8
209
2 out of 7 registries used, show all original rules.
20
Check minimum number of events None
20
Include endpoints None
20
Remove individuals based on genotype QC
19
MYELOFIBROSIS
Control definitions
Control exclude
MYELOPROF
Extra metadata
First used in FinnGen datafreeze
DF2, additional
Not enough data for upset plot.
Or the full data table
Similar endpoints
↥List of similar endpoints to
Myelofibrosis
based on the number of shared cases.
Broader endpoints:
- Myeloproliferative diseases (CML excluded)
- Myeloproliferative diseases
- Neoplasms
- Any event in hilmo or specialist outpatient
- Any prescribed medicine buy
Narrower endpoints:
None
Summary Statistics
↥Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 19 | 7 | 12 |
| Unadjusted prevalence (%) | 0.00 | 0.00 | 0.01 |
| Mean age at first event (years) | 50.57 | 39.96 | 56.76 |
Mortality
Not a core endpoint, no data to show.
Age distribution of first events
Year distribution of first events
Cumulative Incidence
Not a core endpoint, no data to show.
Correlations
↥
Index endpoint: MYELOFIBROSIS – Myelofibrosis
GWS hits:
Survival analyses between endpoints
↥Not a core endpoint, no data to show.
Drugs most likely to be purchased after Myelofibrosis
↥Endpoint not on priority list, no data to show.